Study guide

2.2 Individualized Quality Control Plans, Risk Assessment & CLSI EP23

Diplomate in Laboratory Management ASCP DLM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: DLM Credential Overview & Exam Strategy

1.1 DLM Exam Structure, Computer-Adaptive Delivery & Scoring 1.2 Eligibility Routes, Preparation Strategy & Credential Maintenance

2 Chapter 2: Quality Assurance & Analytical Performance

2.1 Statistical Quality Control, Levey-Jennings Charts & Westgard Multirules 2.2 Individualized Quality Control Plans, Risk Assessment & CLSI EP23 2.3 Method Verification, Validation Protocols & CLSI Standards

3 Chapter 3: Quality Systems, Auditing & Continuous Improvement

3.1 Nonconforming Event Management, Root Cause Analysis & CAPA Systems 3.2 Quality Auditing, Tracer Methodology & Document Control Systems 3.3 Lean Principles, Six Sigma Metrics & Laboratory Process Improvement (DMAIC)

4 Chapter 4: Regulatory Compliance & Accreditation Standards

4.1 CLIA '88 Regulations, Test Complexity Categorization & CMS Licensure 4.2 Deemed Accreditation Organizations (CAP, The Joint Commission, COLA, ISO 15189)

5 Chapter 5: Laboratory Cost Accounting & Financial Fundamentals

5.1 Financial Statements, Accounting Principles & Ratio Analysis in Clinical Labs 5.2 Cost Accounting, Cost-Per-Test Calculations & Break-Even Volume Analysis 5.3 Cash Flow Management, Working Capital & Variance Tracking

6 Chapter 6: Budgeting & Capital Equipment Planning

6.1 Operating Budget Development (Incremental vs. Zero-Based) & Monthly Variance Analysis 6.2 Capital Equipment Acquisition, Net Present Value (NPV), Payback Period & Depreciation 6.3 Vendor Contract Negotiations, Lease Options & Reagent Rental Agreements

7 Chapter 7: Reimbursement, Revenue Cycle & Resource Utilization

7.1 Revenue Cycle Management, Medical Necessity & Coding (CPT, HCPCS, ICD-10-CM) 7.2 Healthcare Reimbursement Models, Clinical Lab Fee Schedule (CLFS) & PAMA 7.3 Laboratory Utilization Management, Diagnostic Stewardship & Test Menu Rationalization 7.4 Materials Management, Inventory Control, Economic Order Quantity & JIT Delivery

8 Chapter 8: Organizational Design, Staffing & Compensation

8.1 Organizational Structure, Leadership Models & Standardized Job Descriptions 8.2 Workload Measurement Systems, FTE Calculations & Staff Scheduling 8.3 Wage and Salary Administration, Market Benchmarking & Total Compensation Design

9 Chapter 9: Talent Acquisition, Retention & Performance

9.1 Recruitment Strategies, Behavioral Interviewing & Legal Separation Protocols 9.2 Employee Onboarding, Training & CLIA '88 Six-Element Competency Assessment 9.3 Performance Management Systems, Annual Reviews & Performance Improvement Plans (PIPs)

10 Chapter 10: Workplace Culture, Relations & Legal Compliance

10.1 Staff Engagement, Retention Strategies & Workplace Recognition Programs 10.2 Conflict Resolution Strategies, Negotiation Tactics & Labor Relations 10.3 Employment Law & Human Resources Compliance (FLSA, FMLA, ADA, EEOC, OSHA)

11 Chapter 11: Strategic Operations, Facilities & Equipment Management

11.1 Strategic Planning, Mission Alignment, Environmental Scanning & SWOT Analysis 11.2 Clinical Laboratory Facility Design, Biosafety Layouts & Ergonomics 11.3 Equipment Lifecycle Management, Preventive Maintenance & Vendor Service Agreements

12 Chapter 12: Laboratory Safety, Biosafety & Emergency Preparedness

12.1 Comprehensive Laboratory Safety Programs (OSHA, Chemical Hygiene, CLSI QMS28) 12.2 Hazardous Chemical and Biohazard Waste Management & Exposure Control Plans 12.3 Disaster Preparedness, Business Continuity & Emergency Operations Planning

13 Chapter 13: Laboratory Informatics, Outreach & Project Leadership

13.1 Laboratory Information Systems (LIS), Middleware & HL7/FHIR Interfaces 13.2 Clinical Data Analytics, LIS Validation, Cybersecurity & HIPAA Protection 13.3 Project Management Frameworks (Agile, Waterfall) & Clinical Implementation Lifecycles 13.4 Outreach Business Operations & Multidisciplinary Clinical Care Teams

2.2 Individualized Quality Control Plans, Risk Assessment & CLSI EP23

Key Takeaways Explain This Topic AI

An IQCP has three required components: Risk Assessment, Quality Control Plan, and Quality Assessment.

The risk assessment evaluates specimen, test system, reagent, environment, and testing personnel across the total testing process.

The laboratory director must approve, sign, and date the QCP before implementation and after material revisions.

An IQCP cannot be less stringent than the manufacturer’s instructions or applicable federal, state, or accreditor requirements.

Pathology is outside the IQCP option; immunohematology may use IQCP only for applicable general QC provisions while all specialty-specific requirements in 42 CFR 493.1271 remain controlling.

Last updated: September 2026

  • Individualized Quality Control Plans, Risk Assessment & CLSI EP23
  • Purpose and regulatory context

The Individualized Quality Control Plan (IQCP) is the CLIA quality-control option that replaced Equivalent Quality Control in 2016. It allows a laboratory to design a risk-based QC system for an eligible nonwaived test, but it is not a waiver from quality requirements. The plan must support accurate, reliable, and timely results for the laboratory's actual setting, operators, specimens, environment, and workflow.

CLSI EP23, Laboratory Quality Control Based on Risk Management , provides a useful framework. Use the current edition; the second edition replaced the older EP23-A document.

Scope and limits

IQCP may be considered for eligible moderate- and high-complexity tests when the manufacturer supplies less than two levels of external control each day of patient testing or when the laboratory wants a documented risk-based plan. Three boundaries govern every plan:

Manufacturer instructions are the floor. An IQCP may add controls but cannot reduce maintenance, calibration, function checks, or QC below the manufacturer's instructions for use.

Other law still applies. More stringent state requirements and applicable accreditation requirements remain in force.

Specialty rules remain in force. Pathology is not eligible for IQCP. Immunohematology is not categorically excluded from every IQCP use, but IQCP cannot replace the specific control requirements in 42 CFR 493.1271. The laboratory must identify which general QC provision is being addressed and preserve every applicable blood-bank requirement.

The safe exam approach is to reject answers that treat IQCP as permission to ignore package inserts or specialty-specific regulations.

Component 1: Risk Assessment

The risk assessment documents reasonably foreseeable failures and existing controls across the entire testing process. CMS identifies five sources:

Specimen: identification, collection, transport, preparation, stability, interference, and suitability.

Test system: hardware, software, calibration, internal controls, failure modes, maintenance, and result flags.

Reagent: shipping, storage, preparation, lot variability, expiration, contamination, and onboard stability.

Environment: temperature, humidity, power, lighting, vibration, dust, water, space, and electromagnetic effects.

Testing personnel: qualifications, training, competency, workload, human factors, and interpretation.

Review preexamination, examination, and postexamination steps. Sources of evidence include manufacturer risk information, package inserts, historical QC and complaints, proficiency testing, regulatory requirements, published data, and the laboratory's own verification and incident records.

A team can use a qualitative matrix or an FMEA-style score. No federal rule establishes one universal RPN cutoff. The laboratory defines and documents its rating method, prioritizes intolerable risk and high-severity hazards, and does not allow arithmetic to hide a catastrophic failure mode.

Component 2: Quality Control Plan

The QCP converts the assessment into specified controls. It should state control materials, levels, frequency, acceptance criteria, built-in controls, procedural controls, calibration and maintenance checks, action when controls fail, result-hold and patient-impact steps, records, responsibilities, and escalation paths.

The plan must meet at least the manufacturer's instructions and all applicable requirements. The laboratory director reviews, approves, signs, and dates the QCP before use. A technical consultant, supervisor, POCT coordinator, or quality manager may develop and administer the plan but does not replace the director's approval responsibility.

Component 3: Quality Assessment

Quality Assessment is the ongoing feedback loop. Monitor whether the selected controls actually detect and prevent error. Useful indicators include QC failures, calibration problems, corrected reports, complaints, specimen rejections, PT results, environmental excursions, operator errors, downtime, and unexpected patient-result patterns.

Reassess the plan when a new instrument, reagent, operator group, location, or specimen type is introduced; the manufacturer changes instructions; a PT failure, complaint, adverse event, or significant QC trend occurs; environmental or workflow conditions change; or routine review shows that a control is ineffective.

Material changes require renewed laboratory-director review and approval. An IQCP is therefore a controlled, living quality document—not a one-time form used to justify reduced external QC.

Applying the framework

Suppose a point-of-care analyzer operates near its maximum validated room temperature on weekends. The team should verify the instrument's environmental limits, measure actual exposure, and determine how the instrument signals an out-of-range condition. Controls might include a calibrated room-temperature monitor, alert response, suspension of testing outside limits, alternate testing access, operator training, and QA review of excursions. Continuous monitoring or software lockout can be strong controls, but they are design choices based on risk and capability—not universal requirements for every IQCP.